Cognition Therapeutics, Inc. provided consolidated earnings guidance for the year ended December 31, 2023. For the year, the company expected net loss to be approximately $25.6 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.9 USD | -6.86% |
|
-12.44% | +2.70% |
06-07 | Chardan Research Initiates Cognition Therapeutics With Buy Rating, $11 Price Target | MT |
05-29 | HC Wainwright Starts Cognition Therapeutics With Buy Rating, $10 Price Target | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.70% | 76.11M | |
+15.19% | 121B | |
+19.91% | 114B | |
+8.24% | 23.61B | |
-19.80% | 20.43B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B |
- Stock Market
- Equities
- CGTX Stock
- News Cognition Therapeutics, Inc.
- Cognition Therapeutics, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023